Navigation Links
Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
Date:9/10/2009

LOS ANGELES, Sept. 10 /PRNewswire/ -- Ritter Pharmaceuticals, Inc. (Ritter) has hired Howard Foyt, M.D., Ph.D., FACP as its new Executive VP, Development & Chief Medical Officer. Dr. Foyt brings 13 years of expertise in drug development to Ritter, as the Company prepares to file an IND for its therapy for Lactose Intolerance.

Dr. Foyt will join Ritter's senior management team and oversee the Company's clinical development efforts. Ritter will take advantage of Dr. Foyt's leadership in drug development within big pharma and biotech companies. For the past three years, Dr. Foyt served as VP, Clinical Development and Chief Medical Officer at Metabasis Therapeutics, where he was responsible for five drugs in clinical development over multiple therapeutic areas. Dr. Foyt had previously worked at Pfizer, where he served as Senior Director and Site Head - Diabetes & Obesity, and earlier at Parke-Davis for over ten years participating in the clinical development of multiple drugs mainly in the metabolic disease field. Prior to joining Parke-Davis, Dr. Foyt was on the faculty at the University of Texas Medical Branch, Galveston, TX. He earned his medical degree and Ph.D. in Cell Biology from Baylor College of Medicine. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

"We are thrilled to have Dr. Foyt on our team," said Ritter Pharmaceuticals' President and CEO Andrew Ritter. "His breadth of clinical development and drug development experience will bring a great deal of scientific rigor and creativity to our development plans."

About Ritter Pharmaceuticals

Ritter is committed to the discovery, development and commercialization of innovative therapies for gastrointestinal diseases. The Company's scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn's disease, and ulcerative colitis. Ritter's ultimate goal is to improve digestive health and overall quality of life.

Ritter's first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.

www.ritterpharma.com


'/>"/>
SOURCE Ritter Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds US and European Radiopharmaceuticals Market Report
2. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
3. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
4. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
5. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
8. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
9. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
11. Isis Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... A ... bar for entry into teacher preparation programs. The NCTQ report suggests, based on a ... entry requirements would significantly improve teacher quality in the U.S. It argues that this ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... to their communities, 16 more public health departments have been awarded national accreditation ... another 4.5 million people into the expanding network of communities across the nation ...
(Date:3/23/2017)... NJ (PRWEB) , ... March 23, 2017 , ... ... Renaissance Oklahoma City Convention Center at 10 North Broadway Avenue, will be an ... hours of relevant, practical instruction in the management of chronic pain. , Oklahoma ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and businesses of the Norwalk and Vermillion areas, celebrates the newest charity ... is a nonprofit, community-based substance abuse prevention and peer recovery support organization ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Cryostat Market is poised ... decade to reach approximately $3.5 billion by 2025. This ... given segments on global as well as regional levels presented in ...
(Date:3/23/2017)... March 23, 2017 Mosaic Life Care, based in St. Joseph, ... process across its network of 58 clinics, located in 22 cities, and its flagship ... innovative ways to improve the delivery of health care to its patients, including the ... ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
Breaking Medicine Technology: